BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening

Glioblastoma multiforme (GBM), the most common type of primary brain tumor, is universally fatal, with a median survival duration ranging from 12-15 months despite maximum treatment efforts. Temozolomide (TMZ) is the current standard of care for GBM patients; however patients usually develop resista...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cancer Res
Main Authors: Ding, Jie, Wu, Shaofang, Zhang, Chen, Garyali, Arnav, Martinez-Ledesma, Emmanuel, Gao, Feng, Pokkulandra, Adarsha, Li, Xiaolong, Bristow, Christopher, Carugo, Alessandro, Koul, Dimpy, Yung, WK Alfred
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895442/
https://ncbi.nlm.nih.gov/pubmed/31815044
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados